Although immune checkpoint inhibitors (ICIs) have substantially extended survival in many patients, most patients do not achieve durable responses on these treatments. There is a substantial unmet need for methods to sensitize more patients to ICIs.…
- Investigator
- Elias Sayour
- Status
- Accepting Candidates
- Ages
- Adults